In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes

Miguel A. Pérez-Velasco , Julio Osuna-Sánchez , Mercedes Millán-Gómez , Michele Ricci , Almudena López-Sampalo , María-Rosa Bernal-López , Ricardo Gómez-Huelgas , Luis M. Pérez-Belmonte
{"title":"In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes","authors":"Miguel A. Pérez-Velasco ,&nbsp;Julio Osuna-Sánchez ,&nbsp;Mercedes Millán-Gómez ,&nbsp;Michele Ricci ,&nbsp;Almudena López-Sampalo ,&nbsp;María-Rosa Bernal-López ,&nbsp;Ricardo Gómez-Huelgas ,&nbsp;Luis M. Pérez-Belmonte","doi":"10.1016/j.medcle.2024.10.023","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The role of in-hospital dipeptidyl peptidase-4 inhibitors in very old patients has not been widely described. This work analyzes the simplification of in-hospital antihyperglycemic management (less insulin use) and reductions in hypoglycemia events using linagliptin in patients aged<!--> <!-->≥<!--> <!-->80 years with type 2 diabetes.</div></div><div><h3>Patients and methods</h3><div>This real-world observational study included hospitalized patients<!--> <!-->≥<!--> <!-->80 years with type 2 diabetes treated with an antihyperglycemic protocol of either basal-bolus insulin or linagliptin between January 2016 and December 2023. A 1:1 propensity score matching analysis was performed.</div></div><div><h3>Results</h3><div>Post-matching, 944 patients were included in each group. The total and basal insulin doses and number of daily injections were significantly lower in the linagliptin group than the basal-bolus insulin group with no differences in glycemic efficacy. Regarding safety, patients on the basal-bolus insulin regimen had more hypoglycemic events. The use of basal-bolus insulin regimen (odds ratio: 4.22; 95% confidence interval: 2.14–6.28; <em>p</em> <!-->&lt;<!--> <!-->0.001), a higher total insulin dose (odds ratio: 3.55; 95% confidence interval: 2.02–5.36; <em>p</em> <!-->&lt;<!--> <!-->0.001) and the number of insulin injections (odds ratio: 2.86; 95% confidence interval: 1.50–4.12; <em>p</em> <!-->=<!--> <!-->0.002) were associated with a greater risk of hypoglycemia. Other hypoglycemia risk factors were older age, moderate–severe functional dependence, moderate–severe dementia, polypharmacy, and complex health status.</div></div><div><h3>Conclusions</h3><div>The linagliptin regimen simplified in-hospital antihyperglycemic management and reduced hypoglycemia events compared to basal-bolus insulin regimen in patients with type 2 diabetes aged<!--> <!-->≥<!--> <!-->80 years. Basal-bolus insulin use and clinical factors were associated with hypoglycemia. The linagliptin regimen could be considered as standard of care for older adult type 2 diabetes patients in the hospital setting.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 7","pages":"Pages 350-357"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625001421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives

The role of in-hospital dipeptidyl peptidase-4 inhibitors in very old patients has not been widely described. This work analyzes the simplification of in-hospital antihyperglycemic management (less insulin use) and reductions in hypoglycemia events using linagliptin in patients aged  80 years with type 2 diabetes.

Patients and methods

This real-world observational study included hospitalized patients  80 years with type 2 diabetes treated with an antihyperglycemic protocol of either basal-bolus insulin or linagliptin between January 2016 and December 2023. A 1:1 propensity score matching analysis was performed.

Results

Post-matching, 944 patients were included in each group. The total and basal insulin doses and number of daily injections were significantly lower in the linagliptin group than the basal-bolus insulin group with no differences in glycemic efficacy. Regarding safety, patients on the basal-bolus insulin regimen had more hypoglycemic events. The use of basal-bolus insulin regimen (odds ratio: 4.22; 95% confidence interval: 2.14–6.28; p < 0.001), a higher total insulin dose (odds ratio: 3.55; 95% confidence interval: 2.02–5.36; p < 0.001) and the number of insulin injections (odds ratio: 2.86; 95% confidence interval: 1.50–4.12; p = 0.002) were associated with a greater risk of hypoglycemia. Other hypoglycemia risk factors were older age, moderate–severe functional dependence, moderate–severe dementia, polypharmacy, and complex health status.

Conclusions

The linagliptin regimen simplified in-hospital antihyperglycemic management and reduced hypoglycemia events compared to basal-bolus insulin regimen in patients with type 2 diabetes aged  80 years. Basal-bolus insulin use and clinical factors were associated with hypoglycemia. The linagliptin regimen could be considered as standard of care for older adult type 2 diabetes patients in the hospital setting.
院内利格列汀对高龄2型糖尿病患者简化管理和降低血糖的作用
介绍和目的院内二肽基肽酶-4抑制剂在高龄患者中的作用尚未得到广泛报道。本研究分析了年龄≥80岁的2型糖尿病患者使用利格列汀简化住院降糖管理(减少胰岛素使用)和降低低血糖事件。患者和方法这项现实世界观察性研究纳入了2016年1月至2023年12月期间接受基础胰岛素或利格列汀降糖治疗的≥80岁2型糖尿病住院患者。进行1:1倾向评分匹配分析。结果经点配后,两组共纳入944例患者。利格列汀组的总胰岛素剂量和基础胰岛素剂量及每日注射次数均显著低于基础胰岛素注射组,但血糖疗效无差异。在安全性方面,基础胰岛素方案的患者有更多的低血糖事件。使用基础注射胰岛素方案(优势比:4.22;95%置信区间:2.14-6.28;p & lt;0.001),总胰岛素剂量较高(优势比:3.55;95%置信区间:2.02-5.36;p & lt;0.001)和胰岛素注射次数(优势比:2.86;95%置信区间:1.50-4.12;P = 0.002)与低血糖的高风险相关。其他低血糖危险因素包括年龄较大、中重度功能依赖、中重度痴呆、多种用药和复杂的健康状况。结论与基础胰岛素方案相比,利格列汀方案简化了≥80岁2型糖尿病患者的住院降糖管理,降低了低血糖事件。基础剂量胰岛素使用和临床因素与低血糖有关。利格列汀方案可以被认为是医院中老年2型糖尿病患者的标准治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信